Ontorpacept
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118) -fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity[1].
Product Specifications
CAS Number
[2131089-46-6]
Product Name Alternative
TTI-621
UNSPSC
12352203
Target
CD47
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ontorpacept.html
Purity
99.57
Solubility
10 mM in DMSO
Smiles
[Ontorpacept]
Molecular Weight
(76.43 kDa)
References & Citations
[1]Petrova PS, et al. TTI-621 (SIRPαFc) : A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. Clin Cancer Res. 2017 Feb 15;23 (4) :1068-1079.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6254282-01 0.1 mL
TCR, alpha, beta (T Cell Receptor, T-cell Receptor beta-1 Chain C Region, TRBC1, T-cell Receptor alpha Chain C Region, TRAC, TCRA) (MaxLight 490)
Ask
View Details 
MBS6254282-02 5x 0.1 mL
TCR, alpha, beta (T Cell Receptor, T-cell Receptor beta-1 Chain C Region, TRBC1, T-cell Receptor alpha Chain C Region, TRAC, TCRA) (MaxLight 490)
Ask
View Details 
